<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2695">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341935</url>
  </required_header>
  <id_info>
    <org_study_id>20200384</org_study_id>
    <nct_id>NCT04341935</nct_id>
  </id_info>
  <brief_title>Effects of DPP4 Inhibition on COVID-19</brief_title>
  <official_title>Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication
      commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity
      of the COVID-19 infection
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Glucose Llevels</measure>
    <time_frame>Baseline, up to 2 weeks</time_frame>
    <description>Change in glucose control will be assessed via glucose levels obtained from blood serum samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in SpO2 levels</measure>
    <time_frame>Baseline, up to 2 weeks</time_frame>
    <description>changes in SpO2 will be measured with a Pulseimetry, an indirect, non-invasive method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Interleukin 6 (IL6)</measure>
    <time_frame>Baseline, up to 2 weeks</time_frame>
    <description>Changes in IL 6 will be assessed from blood serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in chest structures</measure>
    <time_frame>Baseline, up to 2 weeks</time_frame>
    <description>Changes in Chest radiography (X-ray)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>DPP4 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>5 mg Linagliptin administered by mouth once daily</description>
    <arm_group_label>DPP4 group</arm_group_label>
    <other_name>Tradjenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin regimen</intervention_name>
    <description>Standard of care insulin regimen as per hospital protocol</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines

          -  Age â‰¥ 18

          -  Confirmed COVID-19

          -  Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore
             throat, myalgia, nasal congestion, diarrhea

          -  Moderate COVID-19 is defined as &gt; 2 of the following in non-intubated patients: any
             symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with
             bilateral ground glass opacities or bilateral consolidations, SpO2 &lt;90% up to 5L Nasal
             Cannula (NC)

          -  No additional signs or symptoms of severe COVID-19.

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines

          -  History of Diabetic Ketoacidosis (DKA)

          -  History of acute pancreatitis

          -  Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) &lt; 30
             ml/min/1.73 m2

        Exclusion Criteria:

        T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis;
        Chronic or Acute Renal Failure with eGFR &lt; 30 ml/min/1.73 m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Iacobellis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianluca Iacobellis, MD PhD</last_name>
    <phone>3052433636</phone>
    <email>giacobellis@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020 Mar 17;9(1):601-604. doi: 10.1080/22221751.2020.1739565. eCollection 2020.</citation>
    <PMID>32178593</PMID>
  </results_reference>
  <results_reference>
    <citation>Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.</citation>
    <PMID>32224164</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Gianluca Iacobellis</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-Cov 2</keyword>
  <keyword>DPP4</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

